Belzutifan plus lenvatinib versus cabozantinib in patients with previously treated advanced renal cell carcinoma (LITESPARK-011): an open-label, randomised, controlled, phase 3 trial
Robert J. Motzer, Ray McDermott, Se Hoon Park, Mauricio Burotto et autres
2 citationsThe Lancet